Congress vs. Trump: House Moves to Block Marijuana Rescheduling

A Collision Course in Washington

In one of the more remarkable political developments of 2026, members of Congress are actively trying to prevent the Trump administration from following through on its own marijuana rescheduling initiative. The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies has approved a spending bill containing a rider specifically designed to block the Department of Justice from completing the marijuana rescheduling process.

It is not every day that Congress moves to stop a president from implementing a policy that a majority of the American public supports. Yet that is precisely what is happening with cannabis rescheduling, revealing fractures within the Republican Party and the complex political dynamics that continue to define marijuana policy in the United States.

What the Rider Does

Appropriations riders are provisions attached to must-pass spending bills that restrict how federal agencies can use their budgets. They are a well-established congressional tool for shaping policy without going through the full legislative process.

The rider in question would prohibit the DOJ from spending any funds to finalize or implement the rescheduling of marijuana from Schedule I (or, now, to expand Schedule III classification beyond the limited categories already approved). By cutting off the purse strings, Congress can effectively freeze the rescheduling process even if the administration wants to proceed.

This is the same mechanism that Congress has used for years through the Rohrabacher-Blumenauer amendment to prevent the DOJ from spending funds to interfere with state medical marijuana programs. Now, a different faction is using the same tool to constrain cannabis reform rather than protect it.

Why Some Republicans Oppose Their Own President

The opposition to rescheduling from within the president's own party reflects a genuine ideological divide. While Trump's executive order directing the reclassification of marijuana enjoyed broad public support — a Johns Hopkins study found 92% of Americans support some form of rescheduling — a vocal contingent of Republican lawmakers remains philosophically opposed to loosening federal marijuana restrictions.

Their concerns fall into several categories. Some cite public health worries, arguing that rescheduling sends a signal that marijuana is safe when research on long-term effects is still evolving. Others raise law enforcement concerns, believing that rescheduling will complicate drug enforcement at the state and local level. A few frame their opposition in moral or social-conservative terms, viewing marijuana normalization as incompatible with their vision of American culture.

There are also political calculations at play. The appropriations rider may be less about stopping rescheduling permanently and more about extracting concessions on other priorities. In the horse-trading of the appropriations process, cannabis policy can become a bargaining chip for unrelated legislative goals.

The Administration Pushes Forward Anyway

Despite congressional resistance, the Trump administration has shown no signs of backing down. The DOJ announced in April 2026 that it was immediately moving FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued medical license into Schedule III.

This administrative action was taken under existing executive authority, without requiring congressional approval. The appropriations rider, if it survives the full legislative process, could prevent further expansion of rescheduling categories but may not be able to reverse actions already taken.

Acting Attorney General Todd Blanche has been particularly assertive, making public statements about reconsidering cannabis-related prosecutions and signaling a broadly reformist approach to marijuana enforcement. His posture puts the administration on a direct collision course with the appropriations hawks in Congress.

What This Means for the Cannabis Industry

For the cannabis industry, the congressional maneuvering creates uncertainty at the worst possible time. Companies have been making business decisions based on the assumption that rescheduling would proceed — investing in compliance infrastructure, adjusting tax strategies around the elimination of 280E, and planning expansions predicated on a more favorable federal regulatory environment.

If the appropriations rider succeeds in freezing or slowing the rescheduling process, those investments and plans could be thrown into doubt. The stop-and-go nature of federal cannabis policy has been a chronic challenge for the industry, and another reversal would further erode investor confidence.

The financial stakes are enormous. The elimination of Section 280E alone is worth an estimated $2.3 billion in tax relief to the cannabis industry. Any delay in implementing that relief directly impacts the bottom line of every cannabis business in the country.

A Senate Showdown Looms

The House appropriations bill must still pass the full House and then be reconciled with a Senate version. The Senate has historically been more sympathetic to cannabis reform, and the rider may not survive the reconciliation process.

However, the inclusion of the rider in the House bill guarantees that marijuana rescheduling will be a negotiating point in the broader spending debate. Even if it is ultimately removed, it signals to the administration that there are limits to how far Congress will let the executive branch go on cannabis reform without legislative involvement.

Cannabis advocates are already mobilizing to lobby senators to reject the rider. The industry's growing economic footprint — supporting hundreds of thousands of jobs and generating billions in tax revenue — gives it significant political leverage, particularly in states where cannabis businesses are major employers.

The Irony at the Heart of It All

There is a deep irony in the current situation. A Republican president is pushing marijuana reform, and Republican members of Congress are trying to stop him. Meanwhile, Democrats who have long advocated for cannabis reform find themselves in the unusual position of supporting a Trump administration initiative.

This bipartisan scramble reflects the fact that cannabis policy no longer fits neatly into traditional political categories. Public support for legalization crosses party lines, and the economic reality of a nearly $50 billion industry makes pure prohibition increasingly untenable for lawmakers of any political stripe.

The appropriations rider may ultimately be remembered as the last gasp of congressional cannabis prohibitionism, or it may mark the beginning of a more complex legislative battle over how marijuana reform is implemented at the federal level. Either way, it demonstrates that the path to federal cannabis reform, while clearly moving forward, remains anything but straightforward.